Neuropathic pain is a common condition and affecting 40 to 70% of the general population.
Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment.
Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose
methadone in post-herpetic neuralgia patients who remained refractory after first and second
line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an
opioid agent to their current drug regimen.